Hims & Hers Health (NYSE:HIMS) Announces Earnings Results, Beats Estimates By $0.03 EPS

Hims & Hers Health (NYSE:HIMS) issued its earnings results on Monday. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03, Briefing.com reports. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same quarter in the prior year, the firm earned ($0.05) earnings per share. The business’s quarterly revenue was up 45.8% on a year-over-year basis. Hims & Hers Health updated its FY 2024 guidance to EPS and its Q2 2024 guidance to EPS.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $12.36 on Wednesday. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -112.36 and a beta of 0.97. The firm has a 50-day moving average of $14.04 and a 200-day moving average of $10.35. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16.

Insider Activity at Hims & Hers Health

In related news, COO Melissa Baird sold 11,750 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total transaction of $141,940.00. Following the completion of the transaction, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at $6,510,298.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Soleil Boughton sold 4,080 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the transaction, the chief operating officer now owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HIMS shares. Jefferies Financial Group reaffirmed a “hold” rating and issued a $15.00 target price (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Citigroup upped their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and an average price target of $15.07.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.